Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a cell surface receptor ...

EMA’s panel backs a targeted therapy, which reduces lymphadenopathy and restores B-cell populations in patients with activated phosphoinositide 3-kinase delta syndrome.

The data shows that inhibiting TIE2 with rebastinib could prevent new abnormalities from forming in the brain with fewer side effects.

Can we prevent brain hemorrhages without surgery? New research identifies TIE2 as a key driver of cerebral cavernous malformations (CCMs). Discover how the drug rebastinib could provide a safer, ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, ...

Financing led by Access Biotechnology with participation from new and existing investors-- Financing to support advancement of two ...

Pharming Group’s Joenja receives approval in Japan for the treatment of APDS in patients aged 4 years and older: Leiden, the Netherlands Friday, March 27, 2026, 16:00 Hrs [IST] ...

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific ...

International strategy involves submitting a Marketing Authorization Application (MAA) in Europe by Q4 2025, followed by ...